ReviewJournal of clinical medicine2022
Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Prevalence of diplopia among giant cell arteritis patients: a systematic review and meta-analysis.Eye (London, England) · 2026Pooled it
- Time to diagnosis in large vessel vasculitis: insights from a retrospective study at a tertiary rheumatology centre.RMD open · 2026Article
- Automated detection of giant cell arteritis from temporal artery biopsy specimens using deep learning approaches.Scientific reports · 2026Article
- Posterior ischemic optic neuropathy as the main manifestation of giant cell arteritis: a case-based literature review.Reumatologia · 2026Article
- Giant cell arteritis-associated temporomandibular joint arthritis confirmed by imaging.Rheumatology advances in practice · 2026Article
- Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025Article
- Giant Cell Arteritis With Atypical Features: Acute Vision Loss and Marked Eosinophilia Mimicking Systemic Vasculitis.Cureus · 2025Article
- Utilising multiple discharge coding will improve identification of patients with giant cell arteritis: a retrospective analysis of a hospital discharge dataset.Rheumatology international · 2025Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- Review
- Progress in central retinal artery occlusion: a narrative review.The Journal of international medical research · 2023Review
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of blindness, due to acute ischemic ocular events, is the most feared complication of giant cell arteritis (GCA) since the middle of the 20th century. A decrease of its rate has occurred after the advent of corticoid therapy for this vasculitis, but it seems to have stabilized since then. Early diagnosis and treatment of GCA is key to reducing its ocular morbidity. However, it is not uncommon for ophthalmological manifestations to inaugurate the disease, and the biological inflammatory reaction may be mild, making its diagnosis more challenging. In recent years, vascular imaging has opened up new possibilities for the rapid diagnosis of GCA, and ultrasound has taken a central place in fast-track diagnostic processes. Corticosteroid therapy remains the cornerstone of treatment and must begin immediately in patients with visual symptoms and suspicion of GCA. In that situation, the administration route of corticotherapy, intravenous or oral, is less important than its speed of delivery, any hour of delay worsening the prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.